99%Purity NAD+ / MT2 /VIP/ Selank / Semax / SS-31 / KPV / Snap-8 / Melatonin / GHK CU
TDS 129 Inquiries
1627580-64-6
Industrial Grade
99.9%
ShenZhen
DS
5mg*10vials 10mg*10vials 20mg*10vials 30mg*10vials 40mg*10vials 60mg*10vials
2026-09-06
Medical and health products,Peptide products
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionCertificatesBasic Info
-
Product Name:
MOTS-c
Other Name:MOTS-c
CAS No.:1627580-64-6
Molecular Formula:C101H152N28O22S2 • C2HF3O2
InChIKeys:WYTHCOXVWRKRAH-UHFFFAOYSA-N
Molecular Weight:2174.6
Exact Mass:2174.1110958
Categories:
Research-
Class:
Mitochondria-targeted tetrapeptide (Szeto-Schiller peptide)
Status:FDA-approved (Forzinity) — Accelerated Approval 2025
Mechanism:A cell-permeable, synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂) that selectively concentrates in the inner mitochondrial membrane and reversibly binds to cardiolipin, a phospholipid essential for electron transport chain (ETC) function. By stabilizing cardiolipin, SS-31 restores mitochondrial bioenergetics, reduces cytochrome c peroxidase activity, and prevents oxidative damage in cells with impaired mitochondrial function.
Activity note:SS-31 does not act via traditional receptor agonism. It binds cardiolipin with high selectivity in the inner mitochondrial membrane. Functional EC₅₀ values are context-dependent (cell type, stress model). Key electrophysiology studies report mitochondrial membrane potential restoration at nanomolar concentrations.
Source:Szeto HH, et al. AAPS J. 2006;8(2):E277-E283. Birk AV, et al. J Am Soc Nephrol. 2014;25(6):1157-1169.DOI
Clinical Development:FDA:Forzinity (approved 2025-09-19)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Literature:
FDA: Forzinity (NDA 215244) — Accelerated Approval 2025; Genetics in Medicine: TAZPOWER Phase 2/3 results (Thompson et al. 2020); Drugs: Elamipretide First Approval (Springer 2025)
Disclaimer:Elamipretide (Forzinity) is FDA-approved under accelerated approval for Barth syndrome. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Medical and health products,Peptide products
-
Location:
Room 210, 2nd Floor, Office Building No.1, Dezhou Fushite Electric Motor Co., Ltd., North of Xiaoli Road and West of Tianlong Village, Tianqu Sub-district Office
-
Payment Terms:
100% TT in advance
-
Average lead Time:
15
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
51-100
-
Year of Establishment:
2026
-
Certifications:
COA,COA
-
-
Inquiry History129 Inquiries
Country Product Purchase Quantity Date Posted
United States
Mots-C CAS 1627580-64-6
5 G Apr 26, 2026
United States
MOTS-c (Human) Acetate 98% Powder 1627580-64-6 Senwayer
1 G Sep 7, 2023
United States
Bodygrowth Peptides CAS 1627580-64-6 MOTS-c (Human) Acetate peptides powder
1 G Feb 23, 2026
United States
MOTS-c (Human) Acetate peptides powder
1 G Mar 12, 2026
Brazil
MOTS-c 10mg Peptide Raw Material High Purity
10 PCS Feb 17, 2026
United States
Mots-C
1 KG Sep 12, 2025
United States
mots-c
40 MG Aug 5, 2026
United States
Mots-c
5 G Aug 3, 2026
United States
MOTS-c
15 MG Jul 14, 2026
Netherlands
Mots-C 20mg
40 MT Jul 8, 2026
United States
Mots-c
1 G Jun 11, 2026
Australia
Mots-C
1 KG Jun 9, 2026
United States
Mots-c 40mg
10 PCS May 20, 2026
United States
Mots-c
100 G May 19, 2026
United States
Mots-c
1000 MG May 3, 2026
United States
MOTS-C
400 MG May 1, 2026
United States
Mots-c
1 G Apr 24, 2026
United States
Mots-c
1000 KG Apr 24, 2026
United States
Mots-c
20 PCS Apr 22, 2026
United States
MOTS-c
5 MT Apr 13, 2026 Post an enquiry for this product
